Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954

被引:61
|
作者
Race, Paul R.
Lovering, Andrew L.
White, Scott A.
Grove, Jane I.
Searle, Peter F.
Wrighton, Christopher W.
Hyde, Eva I. [1 ]
机构
[1] Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England
[2] Univ Birmingham, Canc Res UK, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England
[3] ML Labs, Keele ST5 5SP, Staffs, England
基金
英国医学研究理事会; 英国生物技术与生命科学研究理事会;
关键词
nitroreductase; CB1954; protein engineering; X-ray structure; gene therapy;
D O I
10.1016/j.jmb.2007.02.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Escherichia coli nitroreductase (NTR) is a flavoprotein that reduces a variety of quinone and nitroaromatic substrates. Among these substrates is the prodrug 5-[aziridin-1-yl]-2,4-dinitrobenzamide (CB1954) that is activated by NTR to form two products, one of which is highly cytotoxic. NTR in combination with CB1954 has entered clinical trials for virus-directed enzyme-prodrug therapy of cancer. Enhancing the catalytic efficiency of NTR for CB1954 is likely to improve the therapeutic potential of this systeni. We previously identified a number of mutants at six positions around the active site of NTR that showed enhanced sensitisation to CB1954 in an E. coli cell-killing assay. In this study we have purified improved mutants at each of these positions and determined their steady-state kinetic parameters for CB1954 and for the antibiotic nitrofurazone. We have also made a double mutant, combining two of the most beneficial single mutations. All the mutants show enhanced specificity constants for CB1954, and, apart from N71S, the enhancement is selective for CB1954 over nitrofurazone. One mutant, T41L, also shows an increase in selectivity for reducing the 4-nitro group of CB1954 rather than the 2-nitro group. We have determined the three-dimensional structures of selected mutants bound to the substrate analogue nicotinic acid, using X-ray crystallography. The N71S mutation affects interactions of the FMN cofactor, while mutations at T41 and FIN affect the interactions with nicotinic acid. The structure of double mutant N71S/FI24K combines the effects of the two individual single mutations, but it gives a greater selective enhancement of activity with CB1954 over nitrofurazone than either of these, and the highest specificity constant for CB1954 of all the mutations studied. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:481 / 492
页数:12
相关论文
共 28 条
  • [11] Virus-directed enzyme prodrug therapy using retrovirally delivered E-coli nitroreductase and CB1954
    McNeish, IA
    Gilligan, MG
    Green, NK
    Roberts, SM
    Kerr, DJ
    Friedlos, F
    Springer, CJ
    Searle, PF
    BRITISH JOURNAL OF CANCER, 1998, 78 (02) : 155 - 156
  • [12] Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector
    Chen, MJ
    Green, NK
    Reynolds, GM
    Flavell, JR
    Mautner, V
    Kerr, DJ
    Young, LS
    Searle, PF
    GENE THERAPY, 2004, 11 (14) : 1126 - 1136
  • [13] Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector
    M-J Chen
    N K Green
    G M Reynolds
    J R Flavell
    V Mautner
    D J Kerr
    L S Young
    P F Searle
    Gene Therapy, 2004, 11 : 1126 - 1136
  • [14] Structure and Dynamics of Three Escherichia coli NfsB Nitro-Reductase Mutants Selected for Enhanced Activity with the Cancer Prodrug CB1954
    Day, Martin A. A.
    Christofferson, Andrew J. J.
    Anderson, J. L. Ross
    Vass, Simon O. O.
    Evans, Adam
    Searle, Peter F. F.
    White, Scott A. A.
    Hyde, Eva I. I.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (06)
  • [15] Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E-coli nitroreductase
    Weedon, SJ
    Green, NK
    McNeish, IA
    Gilligan, MG
    Mautner, V
    Wrighton, CJ
    Mountain, A
    Young, LS
    Kerr, DJ
    Searle, PF
    INTERNATIONAL JOURNAL OF CANCER, 2000, 86 (06) : 848 - 854
  • [16] Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954
    IA McNeish
    NK Green
    MG Gilligan
    MJ Ford
    V Mautner
    LS Young
    DJ Kerr
    PF Searle
    Gene Therapy, 1998, 5 : 1061 - 1069
  • [17] Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E-coli nitroreductase and CB1954
    McNeish, IA
    Green, NK
    Gilligan, MG
    Ford, MJ
    Mautner, V
    Young, LS
    Kerr, DJ
    Searle, PF
    GENE THERAPY, 1998, 5 (08) : 1061 - 1069
  • [18] Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954
    Djeha, AH
    Hulme, A
    Dexter, MT
    Mountain, A
    Young, LS
    Searle, PF
    Kerr, DJ
    Wrighton, CJ
    CANCER GENE THERAPY, 2000, 7 (05) : 721 - 731
  • [19] Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954
    A Hakim Djeha
    Alison Hulme
    Michael T Dexter
    Andrew Mountain
    Lawrence S Young
    Peter F Searle
    David J Kerr
    Christopher J Wrighton
    Cancer Gene Therapy, 2000, 7 : 721 - 731
  • [20] Sensitisation of human ovarian cancer cells to killing by the prodrug CB1954 following retroviral or adenoviral transfer of the E-coli nitroreductase gene
    Searle, PF
    Weedon, SJ
    McNeish, IA
    Gilligan, MG
    Ford, MJ
    Friedlos, F
    Springer, CJ
    Young, LS
    Kerr, DJ
    GENE THERAPY OF CANCER, 1998, 451 : 107 - 113